Evidence map›Paper›PMID 37207615›Full record

ArticleDrug and alcohol dependence2023

"Come try it out. Get your foot in the door:" Exploring patient perspectives on low-barrier treatment for opioid use disorder.

Margaret Lowenstein, Matthew P Abrams, Molly Crowe, Kelsey Shimamoto, Silvana Mazzella, Denise Botcheos, Jennifer Bertocchi, Shawn Westfahl, Judy Chertok, Kristine Pamela Garcia and 3 more

Abstract read
In one paragraph

Article in Drug and alcohol dependence, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Mobile addiction treatment units: a narrative review.Addiction science & clinical practice · 2025
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Margaret LowensteinPerelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States; Center for Addiction Medicine and Policy, University of Pennsylvania, Philadelphia, PA, United States; Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia, PA, United States. Electronic address: margaw@pennmedicine.upenn.edu.
Matthew P AbramsPerelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States.
Molly CrowePerelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States.
Kelsey ShimamotoRowan University School of Medicine, Camden, NJ, United States.
Silvana MazzellaPrevention Point Philadelphia, Philadelphia, PA, United States.
Denise BotcheosPrevention Point Philadelphia, Philadelphia, PA, United States.
Jennifer BertocchiPrevention Point Philadelphia, Philadelphia, PA, United States.
Shawn WestfahlPrevention Point Philadelphia, Philadelphia, PA, United States.
Judy ChertokPerelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States.
Kristine Pamela GarciaPerelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States.
Rachael TruchilPerelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States.
M Holliday-DavisPerelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States.
Shoshana AronowitzLeonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia, PA, United States; University of Pennsylvania School of Nursing, Philadelphia, PA, United States.

Funding

Improving transitions of care for hospitalized patients with opioid use disorderK23DA055087 · NIDA · UNIVERSITY OF PENNSYLVANIA · PI Margaret Lowenstein · 2022 to 2026
$959k
NIDA NIH HHS K23 DA055087
6 · The paper itself

Abstract

purposeLow-barrier treatment is an emerging strategy for opioid use disorder (OUD) care that prioritizes access to evidence-based medication while minimizing requirements that may limit treatment access in more traditional delivery models, particularly for marginalized patients. Our objective was to explore patient perspectives about low-barrier approaches, with a focus on understanding barriers to and facilitators of engagement from the patient point of view.

methodsWe conducted semi-structured interviews with patients accessing buprenorphine treatment from a multi-site, low-barrier mobile treatment program in Philadelphia, PA from July-December 2021. We analyzed interview data using thematic content analysis and identified key themes.

resultsThe 36 participants were 58% male, 64% Black, 28% White, and 31% Latinx. 89% were enrolled in Medicaid, and 47% were unstably housed. Our analysis revealed three main facilitators of treatment in the low-barrier model. These included 1) program structure that met participant needs, such as flexibility, rapid medication access and robust case management services; 2) harm reduction approach that included acceptance of patient goals other than abstinence and provision of harm reduction services on-site; and 3) strong interpersonal connections with team members, including those with lived experience. Participants contrasted these experiences with other care they had received in the past. Barriers related to lack of structure, limitations of street-based care, and limited support for co-occurring needs, particularly mental health.

conclusionsThis study provides key patient perspectives on low-barrier approaches for OUD treatment. Our findings can inform future program design to increase treatment access and engagement for individuals poorly served by traditional delivery models.

Indexed as

BuprenorphineOpioid-Related DisordersAnalgesics, OpioidFemaleHarm ReductionHealth Services AccessibilityHumansMaleOpiate Substitution TreatmentPhiladelphiaAnalgesics, OpioidBuprenorphineBuprenorphineHarm reductionLow-barrier treatmentLow-threshold treatmentMedication for OUDOpioid use disorder

Identifiers

PMID37207615
PMCPMC10330675

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.